Editas Medicine announced the hiring of a new CEO on Thursday — the fourth top executive to lead the troubled maker of gene-editing treatments since 2014.
Gilmore O’Neill takes over as Editas’ CEO on June 1, the company said. He joins from Sarepta Therapeutics, where he served as chief medical officer.
O’Neill replaces Jim Mullen, the chair of Editas’ board who served as CEO for 14 months mostly because the company couldn’t find anyone else to take the job, multiple sources close to the company told STAT. Mullen will become executive chair of Editas following the transition.
Create a display name to comment
This name will appear with your comment